Recherche
-
Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
(Therapies. vol. 78, n° 1, pp. 115-129, 2022-11-25)Article de revue -
High-Dimensional Propensity Score-Adjusted Case-Crossover for Discovering Adverse Drug Reactions from Computerized Administrative Healthcare Databases
(Drug Safety, 2022-02-18)Article de revue -
The risk of dementia in patients using psychotropic drugs: Antidepressants, mood stabilizers or antipsychotics
(Acta Psychiatrica Scandinavica. vol. 145, n° 1, pp. 56-66, 2022-01)Article de revue -
Antiherpetic drugs: a potential way to prevent Alzheimer's disease?
(Alzheimer's Research and Therapy. vol. 14, n° 1, pp. 3, 2022-01-07)Article de revueLibre accès -
Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study
(BMJ. vol. 376, 2022-03-23)Article de revueLibre accès -
Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study
(European Journal of Epidemiology. pp. 1-11, 2022-09-21)Article de revue -
Use of cardiovascular and antidiabetic drugs during COVID19 epidemic in France
(Fundamental & Clinical Pharmacology. vol. 36, n° S1, pp. 94-95, 2022-06)Article de revue -
Bidisciplinary dermatology-pharmacovigilance consultations: Results of a two-year study
(Annales de Dermatologie et de Vénéréologie, 2022-12-07)Article de revue -
Risk of first ischemic stroke and use of antidopaminergic antiemetics: A nationwide case-time-control study
(Fundamental and Clinical Pharmacology. vol. 36, pp. 22-23, 2022-06)Article de revue -
Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study
(The Lancet Regional Health - Europe. vol. 17, 2022-06)Article de revueLibre accès